Meeder Asset Management’s Cytokinetics CYTK Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $3.92K | Sell |
46
-96
| -68% | -$6.89K | ﹤0.01% | 875 |
|
|
2026
Q1 | $9.36K | Buy |
142
+101
| +246% | +$6.42K | ﹤0.01% | 711 |
|
|
2025
Q4 | $2.6K | Sell |
41
-3
| -7% | -$187 | ﹤0.01% | 855 |
|
|
2025
Q3 | $2.42K | Buy |
+44
| New | +$1.81K | ﹤0.01% | 769 |
|
|
2025
Q2 | – | Sell |
-52
| Closed | -$2.09K | – | 889 |
|
|
2025
Q1 | $2.09K | Sell |
52
-24
| -32% | -$1.1K | ﹤0.01% | 866 |
|
|
2024
Q4 | $3.58K | Buy |
+76
| New | +$3.95K | ﹤0.01% | 865 |
|
|
2024
Q3 | – | Sell |
-43
| Closed | -$2.33K | – | 863 |
|
|
2024
Q2 | $2.33K | Buy |
43
+8
| +23% | +$483 | ﹤0.01% | 838 |
|
|
2024
Q1 | $2.45K | Buy |
+35
| New | +$2.71K | ﹤0.01% | 708 |
|
|
2022
Q4 | – | Sell |
-263
| Closed | -$13K | – | 1070 |
|
|
2022
Q3 | $13K | Sell |
263
-6
| -2% | -$289 | ﹤0.01% | 1228 |
|
|
2022
Q2 | $11K | Buy |
269
+61
| +29% | +$2.46K | ﹤0.01% | 1334 |
|
|
2022
Q1 | $8K | Sell |
208
-6
| -3% | -$213 | ﹤0.01% | 1623 |
|
|
2021
Q4 | $10K | Buy |
214
+5
| +2% | +$193 | ﹤0.01% | 754 |
|
|
2021
Q3 | $7K | Buy |
209
+17
| +9% | +$500 | ﹤0.01% | 1792 |
|
|
2021
Q2 | $4K | Buy |
192
+97
| +102% | +$2.28K | ﹤0.01% | 2005 |
|
|
2021
Q1 | $2K | Hold |
95
| – | – | ﹤0.01% | 2065 |
|
|
2020
Q4 | $2K | Buy |
95
+13
| +16% | +$238 | ﹤0.01% | 1465 |
|
|
2020
Q3 | $2K | Hold |
82
| – | – | ﹤0.01% | 1822 |
|
|
2020
Q2 | $2K | Sell |
82
-733
| -90% | -$13.7K | ﹤0.01% | 1755 |
|
|
2020
Q1 | $9K | Buy |
+815
| New | +$10.4K | ﹤0.01% | 1550 |
|
|
2019
Q4 | – | Sell |
-2,652
| Closed | -$31K | – | 2286 |
|
|
2019
Q3 | $31K | Sell |
2,652
-7,342
| -73% | -$92.2K | ﹤0.01% | 1171 |
|
|
2019
Q2 | $112K | Buy |
9,994
+8,011
| +404% | +$77.3K | 0.01% | 728 |
|
|
2019
Q1 | $16K | Buy |
1,983
+1,370
| +223% | +$10.1K | ﹤0.01% | 1128 |
|
|
2018
Q4 | $4K | Sell |
613
-338
| -36% | -$2.48K | ﹤0.01% | 1458 |
|
|
2018
Q3 | $9K | Buy |
+951
| New | +$7.63K | ﹤0.01% | 1182 |
|
|
2018
Q1 | – | Sell |
-479
| Closed | -$4K | – | 1599 |
|
|
2017
Q4 | $4K | Buy |
479
+53
| +12% | +$602 | ﹤0.01% | 1353 |
|
|
2017
Q3 | $6K | Sell |
426
-112
| -21% | -$1.53K | ﹤0.01% | 1200 |
|
|
2017
Q2 | $7K | Buy |
538
+272
| +102% | +$3.78K | ﹤0.01% | 1086 |
|
|
2017
Q1 | $3K | Hold |
266
| – | – | ﹤0.01% | 1248 |
|
|
2016
Q4 | $3K | Buy |
+266
| New | +$2.82K | ﹤0.01% | 901 |
|
Other funds holding CYTK
ACA
Meeder Asset Management's CYTK Position: Q2 2026 in Review
Meeder Asset Management reduced its Cytokinetics (CYTK) stake by 68% in Q2 2026, selling an estimated $6.89K and leaving 46 shares worth $3.92K. The position accounts for ﹤0.01% of the portfolio, ranked #875.
Meeder Asset Management first reported a position in CYTK in Q4 2016 and has held it in 29 quarters since. The position peaked at $112K in Q2 2019. 482 funds tracked by Wall St. Rank hold CYTK as of Q2 2026.
- Meeder Asset Management held 46 shares of Cytokinetics worth $3.92K as of Q2 2026.
- Meeder Asset Management sold 96 Cytokinetics shares in Q2 2026, an estimated $6.89K.
- Cytokinetics made up ﹤0.01% of Meeder Asset Management's portfolio in Q2 2026, its #875 holding.
- Meeder Asset Management first reported a position in Cytokinetics in Q4 2016 and has held it in 29 quarters since.
- Meeder Asset Management's Cytokinetics position peaked at $112K in Q2 2019.
- 482 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2026.
Based on Meeder Asset Management's 13F filing for Q2 2026, filed 7 Aug 2026.